Categories: Automobile

Kia Announces July 2025 Global Sales Results

  • July 2025 global sales of 262,705 units, up 0.3% Y/y
  • Outside of Korea, Kia sold 217,188 units, up 0.9% Y/y
  • Kia RVs led the company’s sales, including Sportage, Seltos and Sorento
  • Solid sales performance was fueled by steady growth in EV and hybrid models

Kia Corporation today announced total global sales of 262,705 units in July 2025, a 0.3 percent increase year over year.

- Advertisement -

Robust sales were driven by constant growth in EV and hybrid models, while strong demand continued for core RV lineup like the Sportage and Seltos SUV.

- Advertisement -

Kia RVs led the company’s sales in July, with the Sportage SUV selling 46,901 units globally. The Seltos SUV backed up this strong market performance with sales of 28,538 units, followed by the Sorento SUV, which sold 17,852 units.

- Advertisement -

Sales outside of Korea

- Advertisement -

Sales outside of Korea, excluding special purpose vehicles, were up 0.9 percent compared with the same period in 2024, to 217,188 units.

- Advertisement -

In markets outside of Korea, the Sportage SUV led the brand’s momentum, recording 41,477 sales, followed by the Seltos SUV with 23,617 units. Combined sales of the K4 and K3, also known as Forte in some markets, totaled 16,813 units.

- Advertisement -

Korea sales

- Advertisement -

In July, Kia sold 45,017 units in the Korean market, a 2.2 percent decrease compared with the same period last year.

- Advertisement -

The Carnival MPV led the company’s passenger vehicle sales in its home market, with 7,211 units sold in July. The Sorento SUV followed, with sales of 7,053, while the Sportage SUV recorded sales of 5,424 units.

- Advertisement -

Kia aims to sustain its sales momentum with the EV lineup, including EV4, EV5 and PV5. By leveraging customer-centric strategies and strategic investments, the company continues to accelerate growth and strengthen its global electrification leadership.

- Advertisement -

Kia global sales – July 2025

- Advertisement -

July 2025

July 2024

YoY change

June 2025

MoM change

2025 YTD
(
July)

2024 YTD
(
July)

YTD change

Korea sales

45,017

46,010

-2.2%

46,003

-2.1%

321,440

321,250

0.1%

Overseas sales

217,188

215,188

0.9%

223,377

-2.8%

1,526,204

1,493,590

2.2%

Special Purpose Vehicle sales

500

600

-16.7%

647

-22.7%

2,597

2,655

-2.2%

Total sales

262,705

261,798

0.3%

270,027

-2.7%

1,850,241

1,817,495

1.8%

Editor’s note

- Advertisement -

* Sales results are based on wholesale unless otherwise specified
* Monthly sales figures provided in this release are unaudited and on a preliminary basis that may be subject to future update
* With the change in business results categorization in 2023, special purpose vehicle sales are recorded separately
* Special purpose vehicles include various specialized vehicles. Their sales figures account for sales in Korea and overseas markets

- Advertisement -
TheNews Market

Recent Posts

FemiCore (Official Website & Authenticity Notice 2026) Counterfeit Risks and What Consumers Should Know

New York City, NY, June 13, 2026 (GLOBE NEWSWIRE) -- The women's health supplement market…

50 minutes ago

Hitch Open Ping-Pong Embodied (HOPE) AI Challenge Joins the 2026 World Humanoid Robot Games, Seeding Advanced Physical AI Against Human Performance

BEIJING, June 13, 2026 (GLOBE NEWSWIRE) -- The 2026 Hitch Open Ping-Pong Embodied AI Challenge…

50 minutes ago

Crypto News Today: AlphaPepe Unveils AlphaSwap Early Access as Bitcoin Price Prediction Eyes $250,000

MONACO, June 12, 2026 (GLOBE NEWSWIRE) -- Crypto news today is turning toward AlphaPepe after…

50 minutes ago

Hexaware Expands Presence in Gujarat with New Delivery Center at GIFT City

MUMBAI, India, LONDON and ISELIN, N.J., June 13, 2026 /PRNewswire/ -- Hexaware Technologies [NSE: HEXT], a…

3 hours ago

Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI…

4 hours ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

June 13, 2026 07:30 ET  | Source: Intellia Therapeutics, Inc. Data from HAELO Phase 3…

4 hours ago